Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aspirin + pantoprazole
- Development stage
- Unknown
- Lead developer
- The Chinese University of Hong Kong
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Aspirin + pantoprazole is a combination therapy investigated by the Chinese University of Hong Kong to manage patients with peptic ulcer bleeding who require ongoing antiplatelet therapy for cardiovascular or cerebrovascular diseases. Aspirin is a salicylate that acts as a non-selective inhibitor of cyclooxygenase (COX-1 and COX-2) enzymes, providing antiplatelet effects by inhibiting thromboxane A2 synthesis. Pantoprazole is a small molecule proton pump inhibitor (PPI) that covalently binds to the H+/K+-ATPase enzyme in gastric parietal cells, effectively reducing gastric acid secretion. This combination aims to provide the necessary cardioprotection of low-dose aspirin while minimizing the risk of recurrent gastrointestinal bleeding through acid suppression. The specific research context refers to a randomized, placebo-controlled trial (NCT00153725) conducted between 2003 and 2006.
- Brand names
- Pantoloc
- Other names
- Aspirin and Pantoloc
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on aspirin + pantoprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aspirin + pantoprazole.